Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Trial Profile

A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pralsetinib (Primary)
  • Indications Adenocarcinoma; Cholangiocarcinoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours; Thyroid cancer
  • Focus Adverse reactions; First in man; Proof of concept; Registrational; Therapeutic Use
  • Acronyms ARROW
  • Sponsors Blueprint Medicines
  • Most Recent Events

    • 13 Aug 2019 According to a CStone Pharmaceuticals media release, first patient has been dosed in china for this study
    • 12 Aug 2019 Planned primary completion date changed from 1 Mar 2021 to 1 Mar 2020.
    • 04 Jun 2019 Safety and antitumor activity results (n=60, data cut off: 19 Dec 2018) presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top